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INTRODUCTION
The association of Epstein-Barr virus (EBV) and B-cell lymphoproliferative disorders (LPDs) is well established. After primary infection at an early stage, EBV persistently infects B-cells in majority of adults, thereby eliciting transformation and multiplication through a variety of complex mechanisms such as the nuclear factor kappa B pathway. [1, 2] Normally, the EBV-induced B-cell proliferation is counterbalanced by immunologic interactions, thus maintaining the EBV-infected cells at a low level. [3] Immunosuppression (IS) with a wide array of agents affects immune surveillance and homeostasis, thus permitting emergence of EBV-LPD. Immunosenescence has also been recently described to be associated with EBV-LPDs. [4] We report a case of a 59-year-old female who developed a mucocutaneous ulcer (MCU) associated with IS, the first case report of EBV-associated MCU from India to the best of our knowledge.
CASE REPORT
A 59-year-old female presented with an ulcer in the inner aspect of her right cheek associated with pain and difficulty in speaking for 2 months. She was a known case of rheumatoid arthritis on methotrexate (MTX) for 15 years. There was no history of trauma, smoking, or tobacco consumption. Clinical examination revealed an infiltrative lesion on the right buccal mucosa involving the lower gingivobuccal sulcus of size 2 cm × 3 cm extending to the alveolus. Regions 46 and 47 appeared indurated with palpable lymph nodes involving the right side of region IB. Systemic examinations were within normal limits. The clinical impression was of carcinoma buccal mucosa. Investigations revealed a normal hemogram; viral markers were negative. Liver and renal functions were normal. Anti-EBV-CA-IgM and qualitative This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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Case Report
The diagnostic morphologic features include (i) well-circumscribed and superficial lesion surrounded by prominent rim of small T-lymphocytes at the base. (ii) Subepithelial infiltrates containing pleomorphic blasts that may be reminiscent of RS cells admixed with a polymorphous infiltrate, eosinophils being prominent sometimes. (iii) The blasts are of B-cell origin with concomitant positivity for CD30, CD45, and EBV in most cases. CD20 is negative in approximately 11.5% of cases, focal/weak staining in approximately 19%. [4] CD15 positivity may be noted, thus mimicking a diagnosis of CHL. In this case, the blasts were positive for CD30 and EBV-LMP1 and focally positive for CD20 and CD79a. (iv) The infiltrate is also known to contain abundant CD8-positive T-cells and large numbers of EBV-positive plasmacytoid apoptotic cells, not common to CHL. Thus, the presence of abundant apoptosis rules out the diagnosis of EBV-associated CHL, its presence being suggestive of preserved normal control mechanisms and lack of a transformed phenotype. [4, 6] In EBV-LPDs associated with MTX, the lack of expression of CD15 in CD30-positive Hodgkin/Reed-Sternberg (HRS)-like cells rules out CHL. [7] An additional parameter not typical for CHL is the wide range in cell size of the EBV-positive cells as highlighted by CD20, CD30, and EBV-encoded RNA. Typically, these cells include some small lymphocytes, immunoblasts, and large HRS-like cells which unlike CHL are CD45 positive. [4] In addition, the CD15-positive cells in CHL do not harbor Oct-2 and Bob-1. A uniform positivity for EBV-LMP1 on immunohistochemistry in a spectrum of cells rules out CHL with an underlying history of MTX-induced IS. The presentation of EBVMCU as an isolated ulcerating lesion without a tumor mass and no systemic involvement rules out the diagnosis of an aggressive posttransplant LPD. [8] As far as the mechanism of action for MTX is concerned for EBVMCU, MTX directly induces EBV replication by activation Gross examination showed mucosa-covered tissue measuring 0.3 cm × 0.2 cm × 0.1 cm.
Microscopy revealed buccal mucosa with ulceration and acute inflammatory exudate. The subepithelial stroma was infiltrated by numerous medium-to-large lymphoid cells with focal angiocentricity displaying enlarged vesicular nuclei, prominent nucleoli, and eosinophilic cytoplasm. Few binucleate cells were present, but classical RS cells were not seen. Admixed were few histiocytes, immunoblasts, and eosinophils. On immunohistochemistry, the neoplastic lymphoid cells were CD30 and EBV-LMP1 positive. CD20 and CD79a were strongly positive in 30% of cells, many being perivascular. The Ki-67-labeling index was 60%. Pan-cytokeratin, CD56, CD3, CD138, CD15, and anaplastic lymphoma kinase-1 were negative [ Figures 1 and 2] .
In view of the history of MTX-induced IS, histology, and supporting immunohistochemistry, a diagnosis consistent with EBV-positive MCU (EBVMCU) was made.
IS was discontinued, and the patient was started on metronidazole leading to healing of the ulcer.
DISCUSSION
Dojcinov et al. first reported the entity EBVMCU in 26 patients, 9 associated with IS caused by MTX, azathioprine, and cyclosporine-A given for autoimmune diseases and 17 with ulceration of the skin or mucosa with no systemic involvement as evident in this case. [4, 5] EBVMCU is an entity associated with IS from a variety of origins, suggesting a common pathogenetic mechanism. The lesion is characterized by an isolated and circumscribed cutaneous and mucosal presentation with an indolent behavior and a self-limited clinical course being thought to have resulted from a minimal and localized lapse in immunosurveillance over EBV. The morphologic and immunophenotypic features at times may be mistaken for classical Hodgkin lymphoma (CHL) due to the overlap with CD15 positivity and CD20. [4] of early viral promoters. [9] Most cases diagnosed with EBVMCU on IS have regressed on withdrawal of the drug. [4] Another close differential is lymphomatoid granulomatosis; however, the lack of pulmonary involvement, strong CD30 positivity, and downregulation of CD20 argues against the diagnosis. CD30+ LPD of the oral cavity is also a differential; however, these tumors are typically negative for EBV-LMP1 and CD20 and positive for T-cell markers. [10] CONCLUSIONS EBVMCU is a unique entity that must be considered as a differential diagnosis of in a case presenting with mucosal ulceration. Differentiation from aggressive lymphoma which is a histologic mimic is essential because EBVMCU due to IS can resolve on withdrawal of immunosuppressive agents.
Financial support and sponsorship
Nil.
